The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release records of specific agreements between the federal government and major drug manufacturers starting in 2025. These agreements must include provisions such as offering lower drug prices based on international rates, providing discounts through government platforms like TrumpRx, or receiving special exemptions from import duties and regulatory reviews. While the bill mandates that most documents be made available in a searchable format, it allows the government to withhold only specific confidential pricing details if legally required by foreign laws or court orders, provided a justification is published. Additionally, the law directs the Congressional Budget Office and the Government Accountability Office to analyze the economic and budgetary impacts of these deals, including effects on Medicare, Medicaid, and drug competition.
The Patients First Act of 2026 modifies how Medicare reimburses physicians and primary care providers to improve access and stabilize payments. It establishes a new hybrid payment model for primary care services from 2027 to 2031, which pays a monthly fee per patient to eligible independent practices while covering specific services like care management and telehealth without cost-sharing for patients. The bill also updates the formula for calculating reimbursement rates to account for high inflation years and requires more frequent updates to the costs used in calculating payments. Additionally, the legislation reforms the performance-based payment system by adding care efficiency measures, creating a task force to recommend new quality metrics, and adjusting penalties for providers who fail to report on certain data.
The Essential Caregivers Act of 2026 requires nursing homes, long-term care hospitals, rehabilitation facilities, and intermediate care facilities to allow two chosen family members or friends to visit residents during times when regular visitation is suspended. These essential caregivers must agree to follow the facility's existing safety and infection control rules, which are no more restrictive than those applied to staff. While facilities can limit access for the first seven days of a suspension or deny entry if a caregiver shows symptoms of a serious infectious disease, they cannot block visits for end-of-life care. Additionally, the bill mandates that complaints about denied access to essential caregivers be investigated and resolved within three days.
HR 7651, the Chloe Cole Act of 2026, prohibits healthcare providers from performing certain medical interventions on minors under 18 aimed at altering physical development to align with gender identity. These "covered interventions" include puberty blockers, hormone treatments, and specific surgeries, but exclude medically necessary care for conditions like disorders of sexual development or traumatic injuries. The bill creates a federal civil lawsuit right for affected minors or their parents against providers who perform such interventions, allowing claims for damages including emotional distress and punitive awards, with strict liability for providers after the law's enactment. It explicitly allows exceptions for legitimate medical treatments and requires providers to prove such exceptions apply if challenged.
HR 7184, the PRESS Act, targets equipment used to manufacture illegal drugs by making it unlawful to sell specific items like tableting machines, gelatin capsules, or related chemicals when the seller knows the equipment will be used to produce controlled substances for unlawful U.S. importation. It directly affects manufacturers and distributors of these drug-making tools who have knowledge or reasonable cause to believe their products will facilitate illegal drug trafficking. The bill adds new prohibitions to the Controlled Substances Act and increases potential prison sentences for violations, with penalties reaching up to 20 years for major offenses involving large quantities of equipment or chemicals. These changes aim to disrupt the supply chain for illicit synthetic drugs by holding equipment sellers accountable for their intended use.
This bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.
HR 3100 amends the National Child Protection Act of 1993 to expand background check requirements. It allows businesses and organizations working with vulnerable populations (like children or elderly individuals) to request background checks for their contractors and for people they license or certify to provide care. The bill modifies the law to include individuals "contracted with" or "licensed/certified by" these organizations as those requiring background checks. This change directly affects organizations serving vulnerable groups, their contractors, and licensed care providers by broadening the scope of background checks mandated under the Act.
HR 3108, the RPM Access Act, increases Medicare reimbursement for remote patient monitoring (RPM) in rural areas by setting a minimum reimbursement floor of 100% for practice expenses and malpractice costs starting in 2026. It requires that RPM services include real-time physician availability to address health issues, use data systems compatible with electronic health records, and mandates providers to report data on cost savings and adherence to medications. The bill directly affects rural Medicare beneficiaries with chronic conditions like heart failure and diabetes, as well as healthcare providers delivering RPM services in underserved rural communities. It also requires a 5-year report to Congress analyzing cost savings from RPM use, including reduced hospitalizations and medication adherence. The law aims to improve access to RPM in rural areas where healthcare shortages are most severe.
Protecting Privacy in Purchases Act This bill prohibits payment card networks from using merchant codes that distinguish firearms retailers from general-merchandise retailers or sporting-goods retailers. The Department of Justice must enforce this bill and report annually on the resulting investigations and cases.
The Sunshine Protection Act of 2025 would make daylight saving time permanent across the United States, ending the current practice of changing clocks twice yearly. It repeals the 1966 law requiring seasonal time changes and adjusts time zone offsets to reflect permanent daylight saving time (e.g., shifting from "4 hours" to "3 hours" in historical references). States that currently opt out of daylight saving time (like Arizona and Hawaii) would retain their existing arrangements, while all other states would adopt permanent daylight saving time unless they choose to stay on standard time. This change would directly affect all U.S. residents by eliminating the need to reset clocks in spring and fall.
This resolution expresses support for the Trump administration's efforts to prevent fraud, waste, and abuse in the Supplemental Nutrition Assistance Program (SNAP). It highlights specific findings from 29 states that shared data, noting issues such as deceased individuals receiving benefits and people using incorrect Social Security numbers. The bill aims to increase transparency and ensure taxpayer dollars are redirected to eligible low-income families rather than being lost to criminal actors.
The Stop Settlement Slush Funds Act of 2026 restricts federal agencies from entering into settlement agreements that require payments to third parties unless those funds directly remedy actual harm or compensate for services rendered. This law prohibits officials from directing settlement money to entities other than the United States for purposes such as slush funds or unrelated projects. To ensure compliance, the bill mandates annual reports to the Congressional Budget Office detailing the distribution of settlement funds and requires federal Inspectors General to publicly report any violations to congressional committees. These reporting requirements are set to expire seven years after the bill is enacted.
